

Special Issue

Vaccination Strategies for SARS-CoV-2, the Causative Agent of COVID-19

Message from the Guest Editors

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus has been responsible for millions of deaths worldwide due to an ongoing pandemic, and accelerated production and deployment of medical countermeasures to combat the virus has been a priority. Although vaccination strategies do exist, continued work is critical to refine approaches to optimize the magnitude and duration of the immune response while reducing the prevalence adverse reactions. For this Special Issue, all papers, reviews, and methodologies examining current and novel vaccines and vaccination strategies are welcome, including (but not limited to) in vitro studies, immunogenicity studies in humans or animals, and efficacy studies in humans or animal models of COVID-19.

Guest Editors

Dr. Sara C. Johnston

Virology Division, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD, USA

Dr. Nusrat Homaira

1. Discipline of Paediatrics, School of Women's and Children's Health, Faculty of Medicine, The University of New South Wales, Sydney 2052, Australia

2. Respiratory Department, Sydney Children's Hospital, Sydney 2031, Australia

Deadline for manuscript submissions

closed (30 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/89650

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).